Urogen Pharma’s (NASDAQ:URGN) lock-up period is set to expire on Tuesday, October 31st. Urogen Pharma had issued 4,473,373 shares in its initial public offering on May 4th. The total size of the offering was $58,153,849 based on an initial share price of $13.00. After the expiration of Urogen Pharma’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

A number of brokerages recently issued reports on URGN. Zacks Investment Research upgraded Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 price target on Urogen Pharma and gave the company a “buy” rating in a report on Monday, August 14th. Finally, Jefferies Group LLC boosted their price target on Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a report on Monday, October 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $28.50.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/24/urogen-pharmas-urgn-lock-up-period-set-to-expire-on-october-31st.html.

Urogen Pharma (URGN) opened at 27.34 on Tuesday. Urogen Pharma has a 12-month low of $13.01 and a 12-month high of $33.77. The stock’s market cap is $355.67 million. The firm’s 50 day moving average price is $29.86 and its 200-day moving average price is $21.46.

Large investors have recently modified their holdings of the company. Alps Advisors Inc. purchased a new position in shares of Urogen Pharma during the second quarter worth approximately $195,000. Shikiar Asset Management Inc. purchased a new position in shares of Urogen Pharma during the third quarter worth approximately $665,000. LLBH Private Wealth Management LLC purchased a new position in shares of Urogen Pharma during the second quarter worth approximately $695,000. Spark Investment Management LLC purchased a new position in shares of Urogen Pharma during the second quarter worth approximately $856,000. Finally, Menora Mivtachim Holdings LTD. purchased a new position in shares of Urogen Pharma during the second quarter worth approximately $2,331,000. 36.06% of the stock is currently owned by institutional investors and hedge funds.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.